Embryonic stem cells and inducible pluripotent stem cells: Two faces of the same coin?

Aging

Volumn 4, Issue 12, 2012, Pages 878-886

  Romeo, Francesco ^a   Costanzo, Francesco ^a   Agostini, Massimiliano ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cell based therapy; Embryonic stem cells; Inducible pluripotent stem cells; Self renewal and differentiation

Indexed keywords

EID: 84874794920     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100513     Document Type: Review

References (96)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS and Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282:1145-1147.
2. Daley GQ. Stem cells: roadmap to the clinic. J Clin Invest. 2010; 120:8-10.
3. Crews L, Patrick C, Adame A, Rockenstein E and Masliah E. Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death Dis. 2011; 2:e120.
4. Yang D, Zhang ZJ, Oldenburg M, Ayala M and Zhang SC. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells. 2008; 26:55-63.
5. Chinta SJ and Andersen JK. Prospects and challenges for the use of stem cell technologies to develop novel therapies for Parkinson disease. Cell Cycle. 2011; 10:4179-4180.
6. Bano D, Zanetti F, Mende Y and Nicotera P. Neurodegenerative processes in Huntington's disease. Cell Death Dis. 2011; 2:e228.
7. Copeland N, Harris D and Gaballa MA. Human umbilical cord blood stem cells, myocardial infarction and stroke. Clin Med. 2009; 9:342-345.
8. Matsumoto S. Islet cell transplantation for Type 1 diabetes. J Diabetes. 2010; 2:16-22.
9. Frank NY, Schatton T and Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010; 120:41-50.
10. Zhao J and Pei G. Why cell reprogramming is functionally linked to aging? Aging (Albany NY). 2011; 3:700.
11. Ratajczak MZ, Kucia M, Liu R, Shin DM, Bryndza E, Masternak MM, Tarnowski M, Ratajczak J and Bartke A. RasGrf1: genomic imprinting, VSELs, and aging. Aging (Albany NY). 2011; 3:692-697.
12. Ratajczak MZ, Shin DM, Ratajczak J, Kucia M and Bartke A. A novel insight into aging: are there pluripotent very small embryonic-like stem cells (VSELs) in adult tissues overtime depleted in an Igf-1-dependent manner? Aging (Albany NY). 2010; 2:875-883.
13. Persons DA. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in betathalassemia patients. Ann N Y Acad Sci. 2010; 1202:69-74.
14. Sekiguchi H, Ii M and Losordo DW. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol. 2009; 219235-242.
15. Song YH, Pinkernell K and Alt E. Stem cell induced cardiac regeneration: fusion/mitochondrial exchange and/or transdifferentiation? Cell Cycle. 2011; 10:2281-2286.
16. Quattrocelli M, Cassano M, Crippa S, Perini I and Sampaolesi M. Cell therapy strategies and improvements for muscular dystrophy. Cell Death Differ. 2010; 17:1222-1229.
17. Takahashi K and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126:663-676.
18. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131:861-872.
19. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA and Lemischka IR. A stem cell molecular signature. Science. 2002; 298:601-604.
20. Casati A, Frascoli M, Traggiai E, Proietti M, Schenk U and Grassi F. Cell-autonomous regulation of hematopoietic stem cell cycling activity by ATP. Cell Death Differ. 2011; 18:396-404.
21. Abdelalim EM and Tooyama I. NPR-A regulates self-renewal and pluripotency of embryonic stem cells. Cell Death Dis. 2011; 2:e127.
22. Richly H, Aloia L and Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2011; 2:e204.
23. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S and Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003; 113:643-655.
24. Molofsky AV, Pardal R and Morrison SJ. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol. 2004; 16:700-707.
25. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M and Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113:631-642.
26. Pesce M, Gross MK and Scholer HR. In line with our ancestors: Oct-4 and the mammalian germ. Bioessays. 1998; 20:722-732.
27. Niwa H, Miyazaki J and Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000; 24:372-376.
28. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N and Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003; 17:126-140.
29. Graham V, Khudyakov J, Ellis P and Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron. 2003; 39:749-765.
30. Basu-Roy U, Ambrosetti D, Favaro R, Nicolis SK, Mansukhani A and Basilico C. The transcription factor Sox2 is required for osteoblast self-renewal. Cell Death Differ. 2010; 17:1345-1353.
31. Matthews JR, Sansom OJ and Clarke AR. Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell Death Differ. 2011; 18:1934-1943.
32. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005; 122:947-956.
33. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006; 38:431-440.
34. Niwa H, Burdon T, Chambers I and Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998; 12:2048-2060.
35. Daheron L, Opitz SL, Zaehres H, Lensch MW, Andrews PW, Itskovitz-Eldor J and Daley GQ. LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells. 2004; 22:770-778.
36. Matsuda T, Nakamura T, Nakao K, Arai T, Katsuki M, Heike T and Yokota T. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. Embo J. 1999; 18:4261-4269.
37. Ying QL, Nichols J, Chambers I and Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell. 2003; 115:281-292.
38. Ono Y, Calhabeu F, Morgan JE, Katagiri T, Amthor H and Zammit PS. BMP signalling permits population expansion by preventing premature myogenic differentiation in muscle satellite cells. Cell Death Differ. 2011; 18:222-234.
39. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci. 2000; 113:3897-3905.
40. Ruzinova MB, Schoer RA, Gerald W, Egan JE, Pandolfi PP, Rafii S, Manova K, Mittal V and Benezra R. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrowderived endothelial cells in spontaneous murine tumors. Cancer Cell. 2003; 4:277-289.
41. Ying QL, Stavridis M, Griffiths D, Li M and Smith A. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol. 2003; 21:183-186.
42. Abbas HA, Pant V and Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle. 2011; 10:3257-3262.
43. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E and Xu Y. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol. 2005; 7:165-171.
44. Mora-Castilla S, Tejedo JR, Hmadcha A, Cahuana GM, Martin F, Soria B and Bedoya FJ. Nitric oxide repression of Nanog promotes mouse embryonic stem cell differentiation. Cell Death Differ. 2010; 17:1025-1033.
45. Xu Y. A new role for p53 in maintaining genetic stability in embryonic stem cells. Cell Cycle. 2005; 4(3):363-364.
46. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J and Frisen J. p53 suppresses the self-renewal of adult neural stem cells. Development. 2006; 133:363-369.
47. Armesilla-Diaz A, Bragado P, Del Valle I, Cuevas E, Lazaro I, Martin C, Cigudosa JC and Silva A. p53 regulates the self-renewal and differentiation of neural precursors. Neuroscience. 2009; 158:1378-1389.
48. Flores ER. p73 is critical for the persistence of memory. Cell Death Differ. 2011; 18:381-382.
49. Agostini M, Tucci P, Chen H, Knight RA, Bano D, Nicotera P, McKeon F and Melino G. p73 regulates maintenance of neural stem cell. Biochem Biophys Res Commun. 2010; 403:13-17.
50. Gonzalez-Cano L, Herreros-Villanueva M, Fernandez-Alonso R, Ayuso-Sacido A, Meyer G, Garcia-Verdugo JM, Silva A, Marques MM and Marin MC. p73 deficiency results in impaired self renewal and premature neuronal differentiation of mouse neural progenitors independently of p53. Cell Death Dis. 2010; 1:e109.
51. Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, Bode D, Dobbelstein M, Bruck W and Moll UM. p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell Death Differ. 2010; 17:1816-1829.
52. Fujitani M, Cancino GI, Dugani CB, Weaver IC, Gauthier-Fisher A, Paquin A, Mak TW, Wojtowicz MJ, Miller FD and Kaplan DR. TAp73 acts via the bHLH Hey2 to promote long-term maintenance of neural precursors. Curr Biol. 2010; 20:2058-2065.
53. Zimmer B, Kuegler PB, Baudis B, Genewsky A, Tanavde V, Koh W, Tan B, Waldmann T, Kadereit S and Leist M. Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death Differ. 2011; 18:383-395.
54. Gangaraju VK and Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol. 2009; 10:116-125.
55. Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, Yamanaka S, Willenbring H and Verdin E. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY). 2010; 2:415-431.
56. He L and Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5:522-531.
57. Houbaviy HB, Murray MF and Sharp PA. Embryonic stem cellspecific MicroRNAs. Dev Cell. 2003; 5:351-358.
58. Singh SK, Kagalwala MN, Parker-Thornburg J, Adams H and Majumder S. REST maintains self-renewal and pluripotency of embryonic stem cells. Nature. 2008; 453:223-227.
59. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV and Hannon GJ. Dicer is essential for mouse development. Nat Genet. 2003; 35:215-217.
60. Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, Livingston DM and Rajewsky K. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev. 2005; 19:489-501.
61. Makeyev EV, Zhang J, Carrasco MA and Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell. 2007; 27:435-448.
62. Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, Forsythe ID, Young KW, Ventura A, Concepcion CP, Han YC, Candi E, Knight RA, et al. microRNA-34a regulates neurite outgrowth, spinal morphology, and function. Proc Natl Acad Sci U S A. 2011; 108:21099-21104.
63. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P, Nicotera P, McKeon F, Knight RA, Mak TW and Melino G. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A. 2011; 108:21093-21098.
64. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II and Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318:1917-1920.
65. Menendez S, Camus S and Izpisua Belmonte JC. p53: guardian of reprogramming. Cell Cycle. 2010; 9:3887-3891.
66. Pelengaris S, Khan M and Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002; 2:764-776.
67. Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W, Zhang Q, Xiang C, Hou P, Song Z, Liu Y, Yong J, Zhang P, et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell. 2008; 3:475-479.
68. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K and Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009; 4601132-1135.
69. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM and Izpisua Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009; 460:1140-1144.
70. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M and Blasco MA. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009; 460(7259):1149-1153.
71. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG and Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009; 460:1145-1148.
72. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010; 17:193-199.
73. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks GG, Hannon GJ, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol. 2011; 13:1353-1360.
74. Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, Ambartsumyan G, Aimiuwu O, Richter L, Zhang J, Khvorostov I, Ott V, Grunstein M, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009; 5:111-123.
75. Okita K, Ichisaka T and Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature. 2007; 448:313-317.
76. Trounson A, Thakar RG, Lomax G and Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011; 9:52.
77. Noren Hooten N and Evans MK. The ultimate transformers: mesenchymal stem cells. Cell Cycle. 2011; 10:4189-4190.
78. Egea V, von Baumgarten L, Schichor C, Berninger B, Popp T, Neth P, Goldbrunner R, Kienast Y, Winkler F, Jochum M and Ries C. TNF-alpha respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma. Cell Death Differ. 2011; 18:853-863.
79. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D and Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003; 102:3837-3844.
80. Semont A, Mouiseddine M, Francois A, Demarquay C, Mathieu N, Chapel A, Sache A, Thierry D, Laloi P and Gourmelon P. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 2010; 17:952-961.
81. Tome M, Lopez-Romero P, Albo C, Sepulveda JC, Fernandez-Gutierrez B, Dopazo A, Bernad A and Gonzalez MA. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ. 2011; 18:985-995.
82. Zhu W, Huang L, Li Y, Qian H, Shan X, Yan Y, Mao F, Wu X and Xu WR. Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth. Cell Cycle. 2011; 10:3198-3207.
83. Anastasia L, Pelissero G, Venerando B and Tettamanti G. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. Cell Death Differ. 2010; 17:1230-1237.
84. Sarig R and Rotter V. Can an iPS cell secure its genomic fidelity? Cell Death Differ. 2011; 18:743-744.
85. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, Ng S, Sourour M, Hamalainen R, Olsson C, Lundin K, Mikkola M, Trokovic R, et al. Copy number variation and selection during reprogramming to pluripotency. Nature. 2011; 471:58-62.
86. Pasi CE, Dereli-Oz A, Negrini S, Friedli M, Fragola G, Lombardo A, Van Houwe G, Naldini L, Casola S, Testa G, Trono D, Pelicci PG and Halazonetis TD. Genomic instability in induced stem cells. Cell Death Differ. 2011; 18:745-753.
87. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011; 471:63-67.
88. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011; 471:68-73.
89. Bogomazova AN, Lagarkova MA, Tskhovrebova LV, Shutova MV and Kiselev SL. Error-prone nonhomologous end joining repair operates in human pluripotent stem cells during late G2. Aging (Albany NY). 2011; 3:584-596.
90. Ohmine S, Squillace KA, Hartjes KA, Deeds MC, Armstrong AS, Thatava T, Sakuma T, Terzic A, Kudva Y and Ikeda Y. Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency. Aging (Albany NY). 2012; 4:60-73.
91. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K and Daley GQ. Diseasespecific induced pluripotent stem cells. Cell. 2008; 134:877-886.
92. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE and Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008; 321:1218-1221.
93. Pfisterer U, Wood J, Nihlberg K, Hallgren O, Bjermer L, Westergren-Thorsson G, Lindvall O and Parmar M. Efficient induction of functional neurons from adult human fibroblasts. Cell Cycle. 2011; 10:3311-3316.
94. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, Li Y, Mu Y, Chen G, Yu D, McCarthy S, Sebat J and Gage FH. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011; 473:221-225.
95. Ye Z, Liu CF and Jang YY. Hematopoietic cells as sources for patient-specific iPSCs and disease modeling. Cell Cycle. 2011; 10:2840-2844.
96. Ho JC, Zhou T, Lai WH, Huang Y, Chan YC, Li X, Wong NL, Li Y, Au KW, Guo D, Xu J, Siu CW, Pei D, et al. Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging (Albany NY). 2011; 3:380-390.